Valuation: Silence Therapeutics plc

Market Cap 320M 428M 375M 348M 605M 40.97B 617M 4.14B 1.63B 20.12B 1.61B 1.57B 69.48B P/E 2026 *
-15.2x
P/E 2027 * -13.5x
Enterprise Value 173M 232M 204M 189M 328M 22.22B 335M 2.25B 881M 10.91B 872M 853M 37.68B EV / Sales 2026 *
69.5x
EV / Sales 2027 * 20.5x
Free-Float
69.36%
Yield 2026 *
-
Yield 2027 * -
1 day+3.14%
1 week-12.85%
Current month-16.03%
1 month+31.71%
3 months+53.54%
6 months+56.01%
Current year+51.64%
1 week 8.91
Extreme 8.91
11
1 month 6.52
Extreme 6.52
11.06
Current year 4.19
Extreme 4.19
11.06
1 year 4.19
Extreme 4.19
11.06
3 years 1.97
Extreme 1.97
27.72
5 years 1.97
Extreme 1.97
27.72
10 years 1.97
Extreme 1.97
35
Manager TitleAgeSince
Chief Executive Officer 72 01/12/2025
Director of Finance/CFO 54 01/02/2022
Chief Tech/Sci/R&D Officer - 01/01/2021
Director TitleAgeSince
Director/Board Member 63 21/06/2018
Chairman 72 01/01/2004
Director/Board Member 65 05/05/2025
Date Insider Type Main position Quantity % Market Cap.
07-06Sell 865,112 0.6105%
01-02Free

Director

90,000 0.0635%
01-02Free

Director

90,000 0.0635%
Change 5-day change 1-year change 3-year change Capi.($)
+3.03%-12.85%+46.82%+54.44% 429M
+0.44%+1.41%+4.25%+10.81% 50.73B
-1.67%-4.33%+373.70%+585.11% 39.73B
+0.01%+1.07%+30.00%-5.22% 34.69B
+1.98%-1.91%+20.39%+53.18% 33.21B
-0.06%-4.63%+2.94%+31.65% 26.76B
-1.91%-1.46% - - 16.8B
-1.50%-6.12%+65.60%+120.67% 15.37B
+0.78%+1.16%+15.53%+17.32% 13.78B
-0.64%-3.00%+10.89%-33.41% 12.85B
Average +0.06%-2.13%+63.35%+92.73% 24.43B
Weighted average by Cap. -0.14%-0.40%+80.17%+122.68%

Financials

2026 *2027 *
Net sales 2.5M 3.34M 2.93M 2.71M 4.72M 320M 4.81M 32.32M 12.68M 157M 12.54M 12.26M 542M 3.44M 4.6M 4.04M 3.74M 6.51M 441M 6.63M 44.57M 17.48M 216M 17.29M 16.91M 747M
Net income -50.34M -67.35M -59.07M -54.71M -95.22M -6.45B -97.07M -652M -256M -3.17B -253M -247M -10.93B -84.67M -113M -99.35M -92.02M -160M -10.84B -163M -1.1B -430M -5.32B -425M -416M -18.39B
Net Debt -146M -196M -172M -159M -277M -18.75B -282M -1.9B -744M -9.21B -736M -720M -31.8B -249M -334M -293M -271M -472M -31.94B -481M -3.23B -1.27B -15.68B -1.25B -1.23B -54.17B
Logo Silence Therapeutics plc
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Employees
88
Date Price Change Volume
14/07/26 $9.290 +2.20% 233,565
10/07/26 $9.090 -7.81% 365,407
09/07/26 $9.860 -0.90% 232,796
08/07/26 $9.950 -1.97% 494,240
07/07/26 $10.15 -4.06% 617,739
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
9.090USD
Average target price
29.17USD
Spread / Average Target
+220.87%

Quarterly revenue - Rate of surprise